一项新协议削减了R21/Matrix-M疟疾疫苗的成本,使Gavi能够在2030年之前多提供3 000万剂,并保护700万多儿童。 A new deal cuts R21/Matrix-M malaria vaccine costs, enabling Gavi to deliver 30 million more doses and protect 7 million more children by 2030.

一项新的定价协议削减了R21/Matrix-M疟疾疫苗的成本,使Gavi能够在2030年之前获得3 000万多剂量,并保护700万多儿童。 A new pricing agreement has slashed the cost of the R21/Matrix-M malaria vaccine, allowing Gavi to secure 30 million more doses by 2030 and protect 7 million additional children. 这笔交易由国际融资机制的预付款供资,节省了多达9 000万美元的资金,加速了负担沉重的非洲国家的准入。 Funded by an advance payment from IFFIm, the deal saves up to $90 million and accelerates access in high-burden African countries. 24个国家已经接种了4 000多万剂疫苗,2024年又有14个国家接种了疫苗,2025年又有7个国家接种了疫苗。 Over 40 million doses have already been delivered across 24 nations, with 14 more countries introducing the vaccine in 2024 and seven in 2025. 世卫组织推荐的两种疟疾疫苗第一年将疟疾病例减少50%以上,增加剂量可提供持久保护。 Both WHO-recommended malaria vaccines reduce cases by over 50% in the first year, with booster doses providing lasting protection. 这一扩展使加维更接近其2030年目标,即为更多5 000万儿童接种疫苗,在全球援助萎缩的同时立即提供救生福利。 The expansion brings Gavi closer to its 2030 goal of vaccinating 50 million more children, offering immediate life-saving benefits amid shrinking global aid.